The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
Dr Samet Sahin from the School of Engineering has received £406,000 funding to develop a simple tool to allow healthcare professionals to quickly and ...
Nova Biomedical issued an urgent software correction for its StatStrip Glucose and Glucose/Ketone Hospital Meter Systems after it found a defect that could transmit incorrect glucose and ketone ...